Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Implementation of Lenacapavir for PrEP in a Community Pharmacy
NCT07210125Phase 4Active, not recruiting
- Sponsor
- Kelley-Ross Pharmacy Group
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lenacapavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Kelley-Ross Pharmacy Group. Primary endpoints: Retention Rate at 1 year, Adherence Rate at 1 year and 1 more. Started Sep 2025; status: active, not recruiting.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07210125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07210125.